Filter Results:
(27)
Show Results For
- All HBS Web (27)
- Faculty Publications (5)
Show Results For
- All HBS Web (27)
- Faculty Publications (5)
Page 1 of 27
Results →
- October 2012
- Teaching Plan
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)
By: Robert F. Higgins
This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details
Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Biotechnology Industry; United States; San Diego
- April 2009 (Revised October 2010)
- Case
Bob Beall at the Cystic Fibrosis Foundation
By: Robert Steven Kaplan and Sophie Hood
Bob Beall is the Chief Executive Officer of the Cystic Fibrosis Foundation (CFF). CFF is an extremely successful organization, but Beall has to determine how to manage the organization through the financial crisis of 2008-2009. In this situation, donations are likely... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Philanthropy and Charitable Giving; Governing and Advisory Boards; Leadership; Crisis Management; Nonprofit Organizations
Kaplan, Robert Steven, and Sophie Hood. "Bob Beall at the Cystic Fibrosis Foundation." Harvard Business School Case 409-107, April 2009. (Revised October 2010.)
- March 2010 (Revised June 2011)
- Teaching Note
Bob Beall at the Cystic Fibrosis Foundation (TN)
By: Robert Steven Kaplan
Teaching Note for 409107. View Details
Keywords: Health Industry
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Biotechnology Industry; Pharmaceutical Industry; San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- 01 Nov 2013
- HBS Seminar
Eric Olson, Chief Scientific Officer at Syros Pharmaceuticals
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Pharmaceutical Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- 30 Mar 2012
- HBS Seminar
Matthew W. Emmens, Executive Chairman,Vertex Pharmaceuticals
- 01 Jan 2005
- News
Joseph J. O'Donnell, MBA 1971
programs. However, when the first of his three children, Joey, was born with cystic fibrosis in 1974, O'Donnell knew he would soon have to move into the private sector. The initial medical bill alone, after... View Details
- 01 Dec 2023
- News
Wide Horizon
very wealthy philanthropist—wasn’t an option. His research did uncover an interesting approach employed by the Cystic Fibrosis Foundation, which required a small royalty in exchange for early stage research... View Details
Keywords: Dan Morrell; Photos by Sarah Wilson
- 31 May 2023
- News
Alumni Achievement Awards 2023
came to Vertex in 2017, there was a medicine finishing early clinical trials with the potential to serve up to 90 percent of patients with cystic fibrosis (CF). In October 2019 that became Trikafta. Now CF... View Details
- 01 Jun 2012
- News
The Power of Philanthropy
When their son Joey died of cystic fibrosis in 1986 at age 12, Kathy and Joe O’Donnell (MBA 1971) vowed to fight the disease. O’Donnell, at the time the president of the Boston Concessions Group, joined with... View Details
- 24 Apr 2014
- News
Finding a cure so that others may benefit
In 1986, Joe O’Donnell (AB 1967, MBA 1971) and his wife, Kathy, founded the Joey Fund in memory of their son, who died as a result of cystic fibrosis. O’Donnell has raised millions to battle the disease, and when asked to help the View Details
- 18 May 2020
- News
Joe O’Donnell Named Harvard Medal Recipient
Campaign, which launched in 2013. The Gazette also notes his philanthropic efforts, which have been focused on cystic fibrosis research through the Joey Fund, which O’Donnell established in 1986 after losing... View Details
- 05 Jun 2006
- Research & Ideas
Using Competition to Reform Healthcare
a disadvantage. Strategic focus is not about narrow specialization, but the pursuit of excellence and deepening penetration in the chosen fields. At Fairview-University Children's Hospital (Minnesota), for example, a long-term commitment to excellence in the area of... View Details
- 28 Jun 2010
- HBS Case
Cincinnati Children’s Hospital Medical Center
implementing a "forcing function" into the operating room process that keeps patients out of the OR until they've received antibiotics, thus reducing surgical site infections. For another project, she selects the hospital's View Details
- 01 Jun 2010
- News
Get Well Soon
implementing a “forcing function” into the operating room process that keeps patients out of the OR until they’ve received antibiotics, thus reducing surgical site infections. For another project, she selects the hospital’s Cystic View Details
- Web
Kraft Accelerator
Investing Harvard Business Publishing Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech Harvard Business Publishing Learn how, and why, we got our start HEAR... View Details
- 04 Sep 2019
- News
Accelerating Scientific Discovery
development of a course that could enhance decision making by providing participants with the knowledge and skills to better manage, fund, and commercialize scientific discoveries that could potentially cure illnesses ranging from Alzheimer’s to View Details
Keywords: Jennifer Gillespie
- Profile
Luc Sirois
for children with cystic fibrosis that teaches them skills to deal with their daily treatment regimens. The pace is scrappy and the conversation engaging. Since launching in 2012, HH hackathons have been... View Details
- 06 May 2008
- First Look
First Look: May 6, 2008
candidates into development. However, several questions related to the integration of Aurora into Vertex were still unresolved, the most pressing being Aurora's major collaboration with the Cystic Fibrosis... View Details
Keywords: Martha Lagace